rosiglitazone has been researched along with palmitic acid in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Flodgren, E; Kotarsky, K; Nilsson, NE; Olde, B; Owman, C | 1 |
| Aursnes, M; Hansen, TV; Holen, T; Nebb, HI; Paulsen, SM; Sæther, T; Tungen, JE; Vik, A | 1 |
| Amri, EZ; Gaillard, D; Grimaldi, PA; Inadera, H; Staccini, L; Teboul, L | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM | 1 |
| McBain, SC; Morgan, NG; Scarpello, JH; Smith, SA; Tadayyon, M; Welters, HJ | 1 |
| Chouinard, M; Chui, PC; Corvera, S; Czech, MP; Lazar, MA; Leszyk, J; Nicoloro, S; Straubhaar, J; Wilson-Fritch, L | 1 |
| Bonen, A; Coort, SL; Coumans, WA; Glatz, JF; Luiken, JJ; van der Vusse, GJ | 1 |
| Brameld, JM; Flux, C; Hurley, MS; Salter, AM | 1 |
| Cassell, PG; Hitman, GA; Marshall, C; Turner, MD | 1 |
| Defrance, F; Gmyr, V; Kerr Conte, J; Lefebvre, B; Lukowiak, B; Moerman, E; Pattou, F; Vandewalle, B | 1 |
| Flodgren, E; Galvanovskis, J; Lundquist, I; Meidute Abaraviciene, S; Olde, B; Salehi, A | 1 |
| Abaraviciene, SM; Lundquist, I; Salehi, A | 1 |
| An, ZM; Wang, C; Xiong, ZY; Zhang, L; Zhang, M | 1 |
| Jang, JE; Jeon, MJ; Kim, EH; Kim, HS; Kim, M; Ko, MS; Koh, EH; Lee, CH; Lee, KU; Leem, J; Park, HS; Park, IS; Yoo, HJ | 1 |
| Wei, LX; Wu, J; Wu, JJ; Yang, LJ; Zou, DJ | 1 |
| Cordonier, EL; Hollinger, FE; Jarecke, SK; Zempleni, J | 1 |
| Chen, L; Ge, X; Hu, X; Huang, X; Jing, J; Jueraitetibaike, K; Ma, R; Pan, P; Qiu, X; Yao, B | 1 |
| Liu, S; Wan, J | 1 |
| Chen, C; Chen, X; Huang, J; Jose, PA; Ni, Y; Ren, H; Shao, M; Su, Q; Wang, Y; Yan, H; Yang, J; Zhang, F; Zhong, J | 1 |
19 other study(ies) available for rosiglitazone and palmitic acid
| Article | Year |
|---|---|
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.
Topics: Aequorin; Animals; Calcium; Cell Line; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Genes, Reporter; Humans; Hypoglycemic Agents; Islets of Langerhans; Mice; Palmitic Acids; Receptors, Cell Surface; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Tissue Distribution | 2003 |
Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects.
Topics: Animals; Cells, Cultured; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Keto Acids; Microalgae; Molecular Structure; Palmitic Acids; PPAR alpha; PPAR gamma; Structure-Activity Relationship | 2018 |
Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Actins; Adipose Tissue; Animals; Biomarkers; Carrier Proteins; Cell Differentiation; Cell Division; Chromans; Clone Cells; Creatine Kinase; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Gene Expression; Glycerolphosphate Dehydrogenase; Hypoglycemic Agents; Linoleic Acid; Linoleic Acids; Mice; Muscles; Myelin P2 Protein; Myogenin; Neoplasm Proteins; Nerve Tissue Proteins; Palmitic Acid; Palmitic Acids; Phenotype; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Expression and functional activity of PPARgamma in pancreatic beta cells.
Topics: Animals; Blotting, Western; Cell Death; Cell Line; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Islets of Langerhans; Male; Palmitic Acid; Polymerase Chain Reaction; PPAR gamma; Protein Isoforms; Rats; Rats, Wistar; Rosiglitazone; Species Specificity; Thiazolidinediones; Transfection | 2004 |
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Blotting, Northern; Blotting, Western; Chaperonin 60; Fatty Acids; Insulin; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Obese; Mice, Transgenic; Microscopy, Fluorescence; Mitochondria; Obesity; Oligonucleotide Array Sequence Analysis; Oxygen; Palmitic Acid; PPAR gamma; RNA, Complementary; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Vasodilator Agents | 2004 |
Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats.
Topics: Adipocytes; Adipose Tissue; Animals; CD36 Antigens; Cell Membrane; Fatty Acid Transport Proteins; Fatty Acids; Female; Hypoglycemic Agents; Membrane Transport Proteins; Muscle, Skeletal; Muscles; Obesity; Palmitic Acid; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Effects of fatty acids on skeletal muscle cell differentiation in vitro.
Topics: Animals; Cell Differentiation; Cell Line; Cells, Cultured; Creatine Kinase; DNA; Dose-Response Relationship, Drug; Fatty Acids; Linoleic Acid; Linoleic Acids, Conjugated; Muscle, Skeletal; Myoblasts; Oleic Acid; Palmitic Acid; Peroxisome Proliferator-Activated Receptors; Peroxisome Proliferators; Pyrimidines; Rats; Rosiglitazone; Thiazolidinediones | 2006 |
Effect of glucolipotoxicity and rosiglitazone upon insulin secretion.
Topics: Animals; Cells, Cultured; Glucose; Insulin; Insulin Secretion; Insulin-Secreting Cells; Oleic Acid; Palmitic Acid; Rats; Rosiglitazone; SNARE Proteins; Thiazolidinediones | 2007 |
PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.
Topics: Adult; Fatty Acids, Nonesterified; Gene Expression Profiling; Humans; Islets of Langerhans; Palmitic Acid; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Palmitate-induced beta-cell dysfunction is associated with excessive NO production and is reversed by thiazolidinedione-mediated inhibition of GPR40 transduction mechanisms.
Topics: Animals; Cell Line; Diazoxide; Female; Humans; Hydrolysis; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nitric Oxide; Nitric Oxide Synthase; Palmitic Acid; Phosphatidylinositols; Receptors, G-Protein-Coupled; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2008 |
Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities.
Topics: Animals; Calcium; Caspase 3; Caspase Inhibitors; Cell Line; Cytokines; Extracellular Signal-Regulated MAP Kinases; Female; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Insulin-Secreting Cells; MAP Kinase Signaling System; Mice; Models, Biological; Nitric Oxide Synthase Type II; Palmitic Acid; Rosiglitazone; Thiazolidinediones | 2008 |
[Protective effect of fibroblast growth factors-21 and rosiglitazone sodium on palmitic acid-induced apoptosis in HIT-T15 cells].
Topics: Animals; Apoptosis; Cell Line; Cricetinae; Fibroblast Growth Factors; Insulin-Secreting Cells; JNK Mitogen-Activated Protein Kinases; Palmitic Acid; Rosiglitazone; Thiazolidinediones | 2010 |
Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate-induced decrease in adiponectin synthesis in 3T3L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Endoplasmic Reticulum Stress; Insulin Resistance; Mice; Mitochondria; Mitochondrial Turnover; Nitric Oxide Synthase Type II; Nuclear Respiratory Factor 1; Obesity; Palmitic Acid; Rosiglitazone; Thiazolidinediones | 2012 |
Rosiglitazone protects against palmitate-induced pancreatic beta-cell death by activation of autophagy via 5'-AMP-activated protein kinase modulation.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Cell Death; Cells, Cultured; Cytoprotection; Drug Evaluation, Preclinical; Enzyme Activation; Hypoglycemic Agents; Insulin-Secreting Cells; Palmitic Acid; Rats; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones | 2013 |
Inhibition of acetyl-CoA carboxylases by soraphen A prevents lipid accumulation and adipocyte differentiation in 3T3-L1 cells.
Topics: 3T3-L1 Cells; Acetyl-CoA Carboxylase; Adipocytes; Animals; Cell Differentiation; Enzyme Inhibitors; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression Regulation; Insulin; Lipid Metabolism; Macrolides; Mice; Oxidation-Reduction; Palmitic Acid; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2016 |
Rosiglitazone ameliorates palmitic acid-induced cytotoxicity in TM4 Sertoli cells.
Topics: Animals; Cell Line; Cell Survival; Cells, Cultured; Gene Expression; Hep G2 Cells; Humans; Hypoglycemic Agents; Lipid Metabolism; Male; Mice, Inbred ICR; Palmitic Acid; PPAR gamma; RNA Interference; Rosiglitazone; Sertoli Cells | 2018 |
Rosiglitazone ameliorates palmitic acid-induced endoplasmic reticulum stress and steroidogenic capacity in granulosa cells.
Topics: Animals; Cell Survival; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Estradiol; Female; Granulosa Cells; Hypoglycemic Agents; Mice; Palmitic Acid; Rosiglitazone; Signal Transduction; Transcription Factor CHOP | 2020 |
Long-Term High-Fat Diet Decreases Renal Insulin-Degrading Enzyme Expression and Function by Inhibiting the PPARγ Pathway.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Insulin; Insulin Resistance; Insulysin; Kidney; Mice; Mice, Inbred C57BL; Mice, Obese; Palmitic Acid; PPAR gamma; RNA, Messenger; Rosiglitazone | 2023 |